Teva Pharma (TEVA) Misses Q2 EPS by 4c, Lowers FY EPS Guidance, Cuts Dividend

Teva Pharma (TEVA) Grinds Lower, Shares Down Another 9%

Teva Pharma (NYSE: TEVA) Grinds Lower, Shares Down Another 9%

Credit Suisse Downgrades Teva Pharma (TEVA) to Neutral

Credit Suisse downgraded Teva Pharma (NYSE: TEVA) from Outperform to Neutral with a price target of $25.00 (from $39.00).

Analyst Vamil Divan said as they look ahead they believe there are still no signs of stabilization for some of the key issues impacting TEVAs core... More

Teva Pharma (TEVA) Cracks Fresh Low, Now Down 19.65%

Teva Pharma (NYSE: TEVA) Cracks Fresh Low, Now Down 19.65%

Teva Pharma (TEVA) Sinks 16% on Weak Results, Outlook

Teva Pharma (NYSE: TEVA) shares sink nearly 16% in pre-open trade following weak results and outlook.

Teva Pharma (TEVA) Lowers Quarterly Dividend 75% to $0.085; 1.1% Yield

Teva Pharma (NYSE: TEVA) declared a quarterly dividend of $0.085 per share, or $0.34 annualized. This is a 75% decrease from the prior dividend of $0.34.

The dividend will be payable on September 14, 2017, to stockholders of record on August 29, 2017, with an ex-dividend date of August 25,... More